Skip to Content

Brain & Spine Tumors Trials

Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained High-Grade Gliomas
Aims: The purpose of this study is to assess the use of a yellow, fluorescent dye in combination with a specialized microscope during brain surgery for the removal of a specific type of tumor called a high-grade glioma. Objectives include measuring patient outcomes and measuring the extent of tumor removal.
Principal Investigator: Julian Bailes, MD
NorthShore Project Number:
EH13-331
Sponsor:
NorthShore University HealthSystem
Contact:
Please call 847.570.4224 with questions regarding the study.
Open to Enrollment:
Yes

Phase I Study of Safety and Tolerability of Acetazolamide With Temozolomide
Aims: This is a Phase I study that examines the rate of dose-limiting side effects in patients with malignant astrocytoma treated with combination acetazolamide (ACZ) and temozolomide (TMZ). Eligible patients must have histologically proven newly diagnosed, O6-methylguanine-DNA methyltransferase (MGMT) methylated WHO grade III or IV astrocytoma and be planning to undergo treatment with standard adjuvant TMZ (after completing treatment with TMZ and ionizing radiation).
Principal Investigator: Ryan Merrell, MD
NorthShore Project Number: EH18-083
Contact: Call 847.570.2025 with questions regarding the study.
Open to Enrollment: Yes

A randomized, Double-blind, Phase II Trial of Surgery, Radiation Theray Plus Temozolomide and Pembroliumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
Aims: The purpose of this study is to find out if adding immunotherapy (pembrolizumab) with or without a vaccine (HSPPC-96) to standard of care treatment for GBM improves survival of newly diagnosed GBM subjects. The standard treatment for GBM consists of surgery to remove the brain tumor, radiation and chemotherapy (temozolomide).
Principal Investigator: Ryan Merrell, MD
NorthShore Project Number: EH18-383
Contact: Call 847.570.2025 with questions regarding the study
Open to Enrollment: Yes

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma
Aims:
The purpose of this Phase III study is to finally attain a clear answer to the long-standing question of which treatment route leads to the best clinical outcome for patients with newly diagnosed WHO grade II meningioma. Subjects will be randomly assigned into one of two groups: Group 1 will be observed following surgery and Group 2 will receive radiation therapy following surgery.
Principal Investigator: Ryan Merrell, MD
NorthShore Project Number: EH18-270
Contact: Call 847-570-2025 with questions regarding the study
Open to Enrollment: Yes

M16‐438: A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti‐Tumor Activity of ABBV‐321 in Subjects with Advanced Solid Tumors Associated with Overexpression of the Epidermal Growth Factor Receptor (EGFR)
Aim: The purpose of this phase 1 study is to gain a better understanding of the safety of ABBV-321 when given to patients with glioblastoma multiforme (GBM) or other advanced solid tumors that overexpress EGFR. EGFR is an important molecule found on some cancer cells and some normal cells of the body. If a tumor shows an increased level of EGFR,  then a tumor may respond to ABBV-321. ABBV-321 is considered an investigational drug by the Food and Drug Administration (FDA). Patients will have their tumor tissue tested for EGFR by a central lab and may be eligible if the results show an increased level of EGFR.
Principal Investigator: Ryan Merrell, MD
Contact: Call 847-570-2025 with questions regarding the study
Open to Enrollment: Soon